Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2019

View Archived Issues

Corralling cellular culprits in autism

Universal editing approach to hemophilia A

A new mouse model of the parasitic helminth Loa loa

Umeclidinium is effective and well tolerated in phase II asthma trial

Phase IIa data presented for ANB-020 in patients with peanut allergy

RPRML acts as tumor suppressor and is a potential new biomarker in gastric cancer

Celgene presents results from phase I APHRODITE study of CC-11050

EXOSC5 as a novel prognostic marker in gastric cancer

Plaque transcriptomic analysis provides insights into Peyronie's disease

New treatment approach developed for allergic asthma

L-MIND study of tafasitamab and lenalidomide in DLBCL meets primary endpoint

MicroRNA 597-5p involved in invasion and metastasis in gastric cancer

FDA clears Abeona's IND for phase I/II study of gene therapy ABO-202 for CLN1 disease

Phase III BEACON CRC study of Braftovi triplet therapy meets primary endpoints

Santhera, University of Basel to work together on gene therapy research for LAMA2 MD

Crinetics begins phase I study of CRN-01941 for neuroendocrine tumors

Allergy Therapeutics reports topline results from phase I study of Acarovac MPL

ABI-009, an mTOR inhibitor, shows promise for treating PAH

JCR initiates phase I trial of long-acting growth hormone JR-142

Valneva reports new data from ongoing phase I study of chikungunya vaccine candidate VLA-1553

Bayer presents compounds for cardiovascular diseases

Toray Industries divulges RORC antagonists

Medshine Discovery synthesizes new Wee1 inhibitors

Novartis describes new KCNH2 activators

Debiopharm initiates exploratory study of Debio-1143 with nivolumab in advanced solid tumors

Oncostellae presents androgen and glucocorticoid receptor antagonists

IMDB recommends continuation of phase III trial of Toca-511/Toca-FC in high-grade glioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...